Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or
 Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local
 treatment available is intralesional (IL) Pentostam injection. During the current study the
 investigators will monitor the adverse effects of this treatment and will follow up the
 recovery of the lesions after Pentostam injections.
Cutaneous leishmaniasis is usually treated by topical intervention. In more severe cases
 intralesional Pentostam injection may be applied. This treatment is extremely efficient but
 painful, however without the known adverse effects of IV Pentostam treatment.

 In this study the investigators will follow systematically all leishmania patients who are
 receiving the intralesional treatment. A structured questionnaire will be filled up in each
 doctor visit.

 The current study goal is to examine the adverse effects and the patient reaction to this
 treatment, and to follow the recovery of lesion(s) after this treatment including the number
 of IL injections which was needed.
Inclusion Criteria:

 -  Cutaneous leishmaniasis patients

 -  Treatment by IL Pentostam

 -  Age above 18 years

 Exclusion Criteria:

 -  Children and pregnant women will not participate in the study